NovaBay Pharmaceuticals (NYSE:NBY) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research note published on Saturday. The brokerage issued a hold rating on the stock.

Separately, Ascendiant Capital Markets lowered their price objective on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating on the stock in a report on Monday, November 11th.

NovaBay Pharmaceuticals Stock Performance

Shares of NovaBay Pharmaceuticals stock opened at $0.64 on Friday. The firm has a market cap of $3.15 million, a PE ratio of -0.01 and a beta of 0.65. The business’s 50 day simple moving average is $0.63 and its 200 day simple moving average is $0.87. NovaBay Pharmaceuticals has a 52-week low of $0.36 and a 52-week high of $9.08.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.